Kaminski HJ, Sikorski P, Coronel SI, Kusner LL Myasthenia gravis: the future is here. J Clin Invest. 2024;134:e179742.
Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203:366–74.
Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O’Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57:172–84.
Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor KC. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020;11:776.
Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, et al. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol. 2011;11:519–24.
Fan Z, Li Z, Shen F, Zhang X, Lei L, Su S, et al. Favorable effects of tacrolimus monotherapy on myasthenia gravis patients. Front Neurol. 2020;11:594152.
Itani K, Nakamura M, Wate R, Kaneko S, Fujita K, Iida S, et al. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis. Neuromuscul Disord. 2021;31:512–8.
Duan W, Peng Y, Jin W, Ouyang S, Yang H. Tacrolimus as single-agent immunotherapy and minimal manifestation status in nonthymoma myasthenia gravis. J Immunol Res. 2021;2021:9138548.
Fan Z, Lei L, Su S, Zhang S, Xie N, Li L, et al. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis. Ann Clin Transl Neurol. 2023;10:589–98.
Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pr Neurol. 2008;4:317–27.
Wu H, Chen L, Zhou X, Wu Y, Yan Y, Zhu Y, et al. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. J Neuroimmunol. 2022;372:577955.
Wu H, Wang Z, Xi J, Liu J, Yan C, Song J, et al. Therapeutic and immunoregulatory effects of tacrolimus in patients with refractory generalized myasthenia gravis. Eur Neurol. 2020;83:500–7.
Bao J, Gao S, Weng Y, Zhu J, Ye H, Zhang X. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets. Rev Neurol. 2019;175:65–72.
De Bruyne R, Bogaert D, De Ruyck N, Lambrecht BN, Van Winckel M, Gevaert P, et al. Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells. Clin Exp Immunol. 2015;180:542–50.
Nielsen SCA, Boyd SD. Human adaptive immune receptor repertoire analysis-past, present, and future. Immunol Rev. 2018;284:9–23.
Minervina A, Pogorelyy M, Mamedov I. T-cell receptor and B-cell receptor repertoire profiling in adaptive immunity. Transpl Int. 2019;32:1111–23.
Xu BY, Giscombe R, Söderlund A, Troye-Blomberg M, Pirskanen R, Lefvert AK. Abnormal T cell receptor V gene usage in myasthenia gravis: prevalence and characterization of expanded T cell populations. Clin Exp Immunol. 1998;113:456–64.
Fozza C, Barraqueddu F, Corda G, Contini S, Virdis P, Dore F, et al. Study of the T-cell receptor repertoire by CDR3 spectratyping. J Immunol Methods. 2017;440:1–11.
Hou XL, Wang L, Ding YL, Xie Q, Diao HY. Current status and recent advances of next generation sequencing techniques in immunological repertoire. Genes Immun. 2016;17:153–64.
Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, et al. Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol. 2017;24:270–5.
Zhong H, Ruan Z, Yan C, Lv Z, Zheng X, Goh LY, et al. Short-term outcome prediction for myasthenia gravis: an explainable machine learning model. Ther Adv Neurol Disord. 2023;16:17562864231154976.
Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884–90.
Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12:380–1.
Lefranc MP. IMGT, the international immunogenetics information system. Cold Spring Harb Protoc. 2011;2011:595–603.
Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM. Analyzing the mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol. 2020;38:1194–202.
Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, et al. Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing. J Immunol. 2017;198:1460–73.
Miao Y, Shi Z, Zhang W, Zhu L, Tang S, Chen H, et al. Immune repertoire profiling reveals its clinical application potential and triggers for neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200134.
Stewart JJ, Lee CY, Ibrahim S, Watts P, Shlomchik M, Weigert M, et al. A Shannon entropy analysis of immunoglobulin and T cell receptor. Mol Immunol. 1997;34:1067–82.
Huang T, Pi C, Xu X, Feng Y, Zhang J, Gu H, et al. Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus. Front Immunol. 2023;14:1307392.
van Bladel DAG, van den Brand M, Rijntjes J, Pamidimarri Naga S, Haacke D, Luijks J, et al. Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements. Mod Pathol. 2022;35:757–66.
Grunewald J, Ahlberg R, Lefvert AK, DerSimonian H, Wigzell H, Janson CH. Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand J Immunol. 1991;34:161–8.
Gigliotti D, Lefvert AK, Jeddi-Tehrani M, Esin S, Hodara V, Pirskanen R, et al. Overexpression of select T cell receptor V beta gene families within CD4+ and CD8+T cell subsets of myasthenia gravis patients: a role for superantigen(s)? Mol Med. 1996;2:452–9.
Lu C, Pi X, Xu W, Qing P, Tang H, Li Y, et al. Clinical significance of T cell receptor repertoire in primary Sjogren’s syndrome. EBioMedicine. 2022;84:104252.
Lee Y, Kim SW, Lee E, Shin HY, Kim M, Lee CY, et al. Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients. Heliyon. 2024;10:e26663.
Arvidsson G, Czarnewski P, Johansson A, Raine A, Imgenberg-Kreuz J, Nordlund J, et al. Multimodal single-cell sequencing of B cells in primary Sjögren’s syndrome. Arthritis Rheumatol. 2024;76:255–67.
Pham MC, Masi G, Patzina R, Obaid AH, Oxendine SR, Oh S, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146:319–36.
Masi G, Chen K, Bayer AC, Bayarri-Olmos R, Pham MC, Wallace A, et al. IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. Brain. 2025;10:awaf410.
Zimmermann M, Rose N, Lindner JM, Kim H, Gonçalves AR, Callegari I, et al. Antigen extraction and B cell activation enable identification of rare membrane antigen specific human B cells. Front Immunol. 2019;10:829.
Liu S, Hou XL, Sui WG, Lu QJ, Hu YL, Dai Y. Direct measurement of B-cell receptor repertoire’s composition and variation in systemic lupus erythematosus. Genes Immun. 2017;18:22–7.
Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, et al. Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 2019;574:122–6.
Wang Q, Feng D, Jia S, Lu Q, Zhao M. B-cell receptor repertoire: recent advances in autoimmune diseases. Clin Rev Allergy Immunol. 2024;66:76–98.
Wu M, Pan W, Jia C, He Z, Zhao M, Tang C, et al. Systemic lupus erythematosus patients contain B-cell receptor repertoires sensitive to immunosuppressive drugs. Eur J Immunol. 2022;52:669–80.
van Lieverloo GGA, Al-Soudi A, Wieske L, Klarenbeek PL, Anang DC, Adrichem ME, et al. B-cell and T-cell receptor repertoire in chronic inflammatory demyelinating polyneuropathy, a prospective cohort study. J Peripher Nerv Syst. 2023;28:69–78.
Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, et al. Single-cell repertoire tracing identifies Rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight. 2020;5:e136471.
Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, Oh S, Waters P, et al. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathol Commun. 2022;10:154.
Nagafuchi Y, Ota M, Hatano H, Inoue M, Kobayashi S, Okubo M, et al. Control of naive and effector CD4 T cell receptor repertoires by rheumatoid-arthritis-risk HLA alleles. J Autoimmun. 2022;133:102907.
Sorosina M, Santoro S, Ferrè L, Mascia E, Clarelli F, Giordano A, et al. Risk HLA variants affect the T-cell repertoire in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200093.
Loh TJ, Lim JJ, Jones CM, Dao HT, Tran MT, Baker DG, et al. The molecular basis underlying T cell specificity towards citrullinated epitopes presented by HLA-DR4. Nat Commun. 2024;15:6201.
Galindo-Feria AS, Sharma RK, Dubnovitsky A, Gerstner C, Kozhukh G, Van Vollenhoven A et al. Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase. Ann Rheum Dis. 2025;85:360–9.
Jiang R, Hoehn KB, Lee CS, Pham MC, Homer RJ, Detterbeck FC, et al. Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proc Natl Acad Sci USA. 2020;117:30649–60.